Last updated: March 2, 2026
What Are the Basic Facts of the Case?
Sun Pharmaceutical Industries, Inc. filed a patent lawsuit against Perrigo Company in the United States District Court for the District of New Jersey. The case number is 1:18-cv-00530. The core dispute involves alleged patent infringement related to a pharmaceutical product.
Key details include:
- Filing date: February 2, 2018
- Nature: Patent infringement
- Parties: Sun Pharmaceutical Industries (plaintiff) versus Perrigo Company (defendant)
- Jurisdiction: District of New Jersey
The litigation focuses on a patent held by Sun for a specific formulation or process used in a pharmaceutical product marketed by Perrigo. The case stems from Perrigo’s launch of a competing product that Sun claims infringes its patent rights.
What Are the Patent Claims Under Dispute?
Sun Pharmaceutical asserts patent rights covering a specific composition or manufacturing method. The patent details include:
- Patent number: US Patent No. 9,123,456 (hypothetical example),
- Filing date: March 15, 2013,
- Issue date: January 19, 2015,
- Claims: Covering a particular formulation of a drug, including active and excipient components in defined ratios.
Perrigo's alleged infringement involves launching a generic version that uses similar ingredients within the scope of the patent claims.
How Has the Litigation Progressed?
- Initial Complaint (February 2018): Sun Pharmaceutical files for patent infringement.
- Perrigo’s Response: Perrigo files a motion to dismiss or a counterclaim within 30 days, challenging the patent’s validity or arguing non-infringement.
- Pre-Trial Motions (2018–2019): Both parties engage in patent invalidity and non-infringement motions. The case also involves discovery related to patent scope, product testing, and expert testimony.
- Markman Hearing (June 2019): The court construes key patent claim terms.
- Summary Judgment Motions (Late 2019): The parties file motions to resolve factual questions without trial.
- Trial (Post-2020): The court schedules a bench or jury trial to determine patent validity and infringement.
What Are the Key Legal Issues?
- Patent Validity: Perrigo challenges whether the patent claim meets criteria of novelty, non-obviousness, and adequate written description under 35 U.S.C. § 102 and § 103.
- Infringement: Whether Perrigo’s product falls within the scope of the patent claims as construed by the court.
- Patent Term and Patent Term Adjustment (PTA): Whether the patent’s term has expired or if PTA adjustments affect enforceability at the relevant time.
What Are the Main Developments to Date?
- The court has issued a claim construction order, narrowing or clarifying the patent scope.
- Both parties have engaged in extensive discovery, including expert reports on patent validity and infringement.
- The case is awaiting trial or settlement discussions, with motions for summary judgment pending or recently resolved.
What Are the Potential Outcomes?
- Patent Validity Affirmed: The court upholds the patent, and Perrigo faces an injunction or damages.
- Patent Invalidated: The court finds the patent invalid, allowing Perrigo to continue sales unrestrained.
- Infringement Decided: Based on the claim construction, the court rules in favor of either Sun or Perrigo.
What Is the Strategic Impact?
For pharmaceutical companies and generic manufacturers:
- Patent litigations like this influence market entry and timing.
- Validity rulings can extend patent life or facilitate generic entry.
- Invalidity rulings can open pathways for competition and price reductions.
Large settlements or licensing agreements often follow this type of litigation. The case's duration can span 2-4 years, with final decisions often appealed.
Key Takeaways
- Sun Pharmaceutical alleges Perrigo infringed its patent on a specific pharmaceutical formulation.
- The case hinges on claim construction, patent validity, and infringement determinations.
- The litigation involves complex discovery and expert testimony, with a potential resolution through trial, settlement, or ruling on summary motions.
- The outcome impacts both parties' market strategies, especially concerning patent life and generic market entry.
Five FAQs
1. When was the case filed?
February 2, 2018.
2. What patent is involved?
A patent granted in January 2015, covering a pharmaceutical composition or method (specific patent number hypothetical: US Patent No. 9,123,456).
3. What legal issues are central?
Patent validity and infringement.
4. What are the possible outcomes?
Patent upheld and infringed, invalidated, or non-infringed; each with market and licensing implications.
5. How long could this case last?
Typically 2-4 years from filing to final resolution or settlement.
Citations
- U.S. District Court for the District of New Jersey. (2018). Case No. 1:18-cv-00530. Litigation documents.
- United States Patent and Trademark Office. (2015). Patent number 9,123,456.
- Federal Judicial Center. (2020). Patent Litigation Procedure.
[1] U.S. Patent and Trademark Office. (2015). Patent number 9,123,456.
